Ma E - Search Results

1

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.

Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A. Skarbnik AP, et al. Among authors: ma e. Leuk Lymphoma. 2017 Aug;58(8):1968-1972. doi: 10.1080/10428194.2016.1272688. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28092998 No abstract available.

2

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL. Knopf KB, et al. Among authors: ma e. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. doi: 10.1016/j.clml.2014.03.005. Epub 2014 Jun 11. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25023616

3

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Kumar SK, et al. Among authors: ma e. Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14. Leukemia. 2016. PMID: 26271606 No abstract available.

4

Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).

Gnanasakthy A, DeMuro C, Clark M, Haydysch E, Ma E, Bonthapally V. Gnanasakthy A, et al. Among authors: ma e. J Clin Oncol. 2016 Jun 1;34(16):1928-34. doi: 10.1200/JCO.2015.63.6480. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069082

5

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.

Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, Engstrom A, Sajosi P, Briggs A, Bonthapally V. Parker C, et al. Among authors: ma e. J Med Econ. 2017 Jan;20(1):8-18. doi: 10.1080/13696998.2016.1219358. Epub 2016 Aug 11. J Med Econ. 2017. PMID: 27472034 Free article.

6

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.

Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ. Ma E, et al. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):625-636.e3. doi: 10.1016/j.clml.2016.08.006. Epub 2016 Aug 10. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27686689 Free article.

7

Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.

Gautam A, Zhu Y, Ma E, Lee SY, Zagadailov E, Teasell J, Richhariya A, Bonthapally V, Huebner D. Gautam A, et al. Among authors: ma e. Leuk Lymphoma. 2018 Jan;59(1):69-76. doi: 10.1080/10428194.2017.1324160. Epub 2017 Jun 5. Leuk Lymphoma. 2018. PMID: 28583027

8

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Hux M, Zou D, Ma E, Sajosi P, Engstrom A, Selby R, Benson E, Briggs A, Bonthapally V. Hux M, et al. Among authors: ma e. J Health Econ Outcomes Res. 2016 Oct 26;4(2):188-203. doi: 10.36469/9820. eCollection 2017. J Health Econ Outcomes Res. 2016. PMID: 37661948 Free PMC article.

9

Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.

Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Yang H, et al. Among authors: ma e. J Med Econ. 2017 Oct;20(10):1056-1065. doi: 10.1080/13696998.2017.1355310. Epub 2017 Jul 31. J Med Econ. 2017. PMID: 28703659 Free article.

10

Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.

Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, Cheng WW, Flahavan EM, Kota V, Greenwald DR. Gershon A, et al. Among authors: ma e. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):e222-e231. doi: 10.1016/j.clml.2023.02.002. Epub 2023 Feb 11. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36925388 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,463 results

Search Page

Filters